Диссертация (1141195), страница 23
Текст из файла (страница 23)
J Neuroendocrinol. 2002Sep;14(9):753-9.271. Van der Holt B, Van den Heuvel-Eibrink MM, Van Schaik RH, van derHeiden IP, Wiemer EA, Vossebeld PJ, Löwenberg B, Sonneveld P. ABCB1 genepolymorphisms are not associated with treatment outcome in elderly acute myeloidleukemia patients. Clin Pharmacol Ther. 2006 Nov;80(5):427-39.272.
Van Der Vring J.A. et al. Combination of calcium channel blockers and betaadrenoreceptor blockers for patients with exercise induced angina pectoris: a doubleblind parallel-group comparison of different classes of calcium channel blockers.Netherlands Working Group of Cardiovascular Research (WCN).
British J ClinPharmacol 1999 47(5) 493-8273. Vibeke Andersen, Mette Østergaard, Jane Christensen, Kim Overvad, AnneTjønneland, and Ulla Vogel Polymorphisms in the xenobiotic transporter MultidrugResistance 1 (MDR1) and interaction with meat intake in relation to risk ofcolorectal cancer in a Danish prospective case-cohort study. BMC Cancer. 2009; 9:407.274. Vignalou JB, Huerre Y, de la Briolle A, Allanic F, Beygui F, Barthélémy O,Montalescot G, Collet JP. Clinical, angiographic, and genetic factors associated withearly coronary stent thrombosis. JAMA.
2011 Oct 26;306(16):1765-74.158275. Vilaboa NE, Galán A, Troyano A, de Blas E, Aller P. Regulation of multidrugresistance 1 (MDR1)/P-glycoprotein gene expression and activity by heat-shocktranscription factor 1 (HSF1).JBiolChem. 2000 Aug 11;275(32):24970-6.276. Wang D., Johnson A.D., Papp A.C., Kroetz D.L., Sadee W. Multidrugresistance polypeptide 1 (MDR1, ABCB1) variant 3435C>Taffects mRNAstability.// Pharmacogenet.
Genomics. 2005. Vol. 15(10). P. 693-704.277. Weisburg JH, Curcio M, Caron PC, Raghu G, Mechetner EB, Roepe PD,Scheinberg DA The multidrug resistance phenotype confers immunologicalresistance. J Exp Med. 1996 Jun 1;183(6):2699-704.278. Winkelmann B., Hager J., Kraus W. et al. Genetics of coronary heart disease:Current knowledge and research principles // Am Heart J.- 2000.- Vol.
140.-No4.279. Winkelmann BR, Hager J.. Genetic variation in coronary heart disease andmyocardialinfarction:methodologicaloverviewandclinicalevidence.J.Pharmacogenomics. 2000 Feb;1(1):73-94.280. Xie Y, Liu J, Liu Y, Klaassen CD, Waalkes MP. Toxicokinetic and genomicanalysis of chronic arsenic exposure in multidrug-resistance mdr1a/1b(-/-) doubleknockout mice. Mol Cell Biochem.
2004 Jan; 255(1-2):11-8.281. Zhang Y, Jiang XH, Hu YQ, Li ZR, Su L, Wang ZG, Ma G. MDR1 genotypesdo not influence the absorption of a single oral dose of 600 mg valacyclovir inhealthy Chinese Han ethnic males. Br J Clin Pharmacol. 2008 Aug;66(2):247-54.Epub 2008 May 6282. Zhao Y, Zhai D, He H, Li T, Chen X, Ji H. Effects of CYP3A5, MDR1 andCACNA1C polymorphisms on the oral disposition and response of nimodipine in aChinese cohort. Eur J Clin Pharmacol.
2009 Jun;65(6):579-84.283. Zhou SF.Structure, function and regulation of P-glycoprotein and its clinicalrelevance in drug disposition.Xenobiotica. 2008 Jul;38(7-8):802-32.159.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
